https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

ASCO 2025: Age-Related Differences in Relapsed/Refractory ALL Treatment Outcomes

ASCO 2025: Age-Related Differences in Relapsed/Refractory ALL Treatment Outcomes

Obecabtagene autoleucel shows promising efficacy and safety in treating relapsed/refractory B-ALL, benefiting patients of all ages, including older adults.

administrator

Related Articles